The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: Exploring interactions with biomarkers of Alzheimer disease

JAMA Neurology

Volumn 72, Issue 5, 2015, Pages 520-529

  Hohman, Timothy J ^a,b   Bell, Susan P ^a,b   Jefferson, Angela L ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; VASCULOTROPIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT; VASCULOTROPIN A;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DECLINE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ATROPHY; MILD COGNITIVE IMPAIRMENT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOMARKERS; CROSS-SECTIONAL STUDIES; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY, EPISODIC; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; TAU PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84982131470     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.4761     Document Type: Article

References (33)

1. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114(pt 5):853-865.
2. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130(4):691-703.
3. Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev.2014; 33(2-3):581-594.
4. Storkebaum E, Carmeliet P. VEGF: a critical player in neurodegeneration. J Clin Invest. 2004;113 (1):14-18.
5. Mateo I, Llorca J, Infante J, et al. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand. 2007;116(1):56-58.
6. Provia J, Jeynes B. Reduction in vascular endothelial growth factor expression in the superior temporal, hippocampal, and brainstem regions in Alzheimer's disease. Curr Neurovasc Res. 2014;11(3): 202-209.
7. Garcia KO, Ornellas FLM, Martin PKM, et al. Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease. Front Aging Neurosci. 2014;6: 30.
8. Wang P, Xie ZH, Guo YJ, et al. VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun. 2011;411(3): 620-626.
9. Religa P, Cao R, Religa D, et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep. 2013;3:2053.
10. Tarkowski E, Issa R, Sjögren M, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002;23(2):237-243.
11. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006;21 (1):9-15.
12. Guo L-H, Alexopoulos P, Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2013;263(7):553-560.
13. Paterson RW, Bartlett JW, Blennow K, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014;4:e419.
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121(5):597-609.
15. Jagust WJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia.Neurology. 2009;73(15):1193-1199.
16. Mattsson N, Insel P, Nosheny R, et al; Alzheimer's Disease Neuroimaging Initiative. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. 2014;35(3):614-622.
17. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al; Alzheimer's Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav.2012;6(4):502-516.
18. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al; Alzheimer's Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517-527.
19. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685-691.
20. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis, I: segmentation and surface reconstruction.Neuroimage. 1999;9(2):179-194.
21. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis, II: inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9(2):195-207.
22. Fischl B, Sereno MI, Tootell RBH, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 1999;8(4):272-284.
23. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.
24. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage.2012;61 (4):1402-1418.
25. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3): 968-980.
26. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001;28 (2):131-138.
27. Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol. 2001;22(6):1030-1036.
28. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med. 2001;15(2):85-92.
29. Spuch C, Antequera D, Portero A, et al. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Biomaterials. 2010;31(21):5608-5618.
30. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging. 2004;25(3):283-290.
31. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204.
32. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons.Ann Neurol. 2007;62(1):59-66.
33. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.